DALLAS, December 10, 2014 /PRNewswire/ --
ReportsnReports.com adds Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth and Global Type 2 Diabetes Therapeutics Market 2015-2019 research reports to its store.
The value of type 2 diabetes market in the Asia-Pacific (APAC) markets (for the purposes of this report, APAC refers to Australia, China, India and Japan only), is expected to increase from $6.5 billion in 2013 to $10.5 billion in 2020 at a Compound Annual Growth Rate (CAGR) of 7.1%. Among the four APAC type 2 diabetes markets, Japan has the highest market share of 51% followed by China with 30% and India with 14%. In a best-case scenario, the total market size is expected to grow at a CAGR of 8.1% to $11.2 billion by the end of 2020, while in a worst-case scenario it is expected to grow at a slower CAGR of 6.6% to $10.2 billion by the end of 2020. Should the expensive drug classes mentioned above capture substantial market shares, market growth would be even more robust. Complete report on Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth is available at http://www.reportsnreports.com/reports/320358-type-2-diabetes-therapeutics-in-asia-pacific-markets-to-2020-increasing-uptake-of-novel-drug-classes-to-drive-market-growth.html .
The type 2 diabetes market contains a wide range of drugs that are used to treat patients at different points in the treatment algorithm. The market landscape is dense, with a number of drugs competing for different market segments. Although the first-line therapy is usually metformin, a generic drug, it is often unable to bring the disease under control. Second-line therapy involves the use of other drugs in combination with metformin, and at this stage of the treatment algorithm competition between products is very strong. The established second-line therapy involves the use of sulfonylureas, a highly generalized class of drugs, in combination with metformin. The usage of this class of drug is likely to decline in future, due to the recent approval of superior products and the anticipated approval of stronger products over the 2013-2020 forecast period.
The strong type 2 diabetes APAC market growth is forecast due to the anticipated approval of products in relatively novel treatment classes, such as Glucagon-Like Peptide-1 (GLP-1) agonists, Dipeptidyl Peptidase-4 (DPP-4) inhibitors and Sodium Glucose Transporter-2 (SGLT-2) inhibitors; and the growth of the type 2 diabetes prevalence population in the APAC region, especially in India and China.
Strong Pipeline Containing a Diverse Set of Products
The pipeline for type 2 diabetes contains 591 products, distributed relatively evenly between the different stages of development with the exception of the Preclinical stage, which accounts for 42% of the entire pipeline. 20 products have been identified as being in the registration process for marketing approval, although many of these are novel formulations or combinations of existing products, and are not expected to influence the market to a great degree compared with entirely novel products. The active pipeline molecules, which amount to 591, consist of the following:
• Discovery Phase: 14% or 83 molecules
• Investigational New Drug (IND)/Clinical Trial Approval (CTA)-filed Phase: 1% or four molecules
• Preclinical Phase: 42% or 248 molecules
• Phase I: 14% or 84 molecules
• Phase II: 15% or 988 molecules
• Phase III: 8% or 46 molecules
• Pre-registration: 3% or 20 molecules
• Undisclosed: 3% or 18 molecule
Six late-stage pipeline products are expected to be launched during the forecast period, such as dulaglutide, albiglutide, trelagliptin, and tofogliflozin. There are six more molecules that are only available in part of the APAC region but that are expected to be launched in the remaining countries during the forecast period, such as lixisenatide, which is marketed in Australia but has not yet been approved in India, China and Japan. However, the new pipeline does not include any novel Mechanisms of Action (MoA) and is dominated by drug MoAs that have already been marketed, such as SGLT, DPP-4, and GLP-1 receptor agonist. Order a copy of Type 2 Diabetes Therapeutics in Asia-Pacific Markets to 2020 - Increasing Uptake of Novel Drug Classes to Drive Market Growth research report at http://www.reportsnreports.com/Purchase.aspx?name=320358 .
The Global Type 2 Diabetes Therapeutics market is forecast to grow at 7.15% CAGR over the period 2014-2019. To calculate the market size, the Global Type 2 Diabetes Therapeutics Market 2015-2019 report considers revenue generated through the sales of drugs like DPP-4 inhibitors, Biguanides, Insulins, GLP-1 receptor agonists, Thiazolidenediones, Sulfonulureas, SGLT-2 inhibitors, a-Glucosidase inhibitors and others (amylinomimetics, bile acid sequestrants, and dopamine receptor agonists). Complete report is available at http://www.reportsnreports.com/reports/320342-global-type-2-diabetes-therapeutics-market-2015-2019.html .
Geographically, the global type 2 diabetes therapeutics market report covers Americas (US, Brazil, and Mexico), 5EU (France, Germany, Italy, Spain, and UK) and APAC (China, Japan, India, Russia, and other APAC countries). Increase in academia-industry collaboration stimulating growth in this industry. One major trend upcoming in this market is the increasing focus on emerging markets. As a result of an increase in the diabetic population, and increased accessibility to disease monitoring and disease management devices, key vendors have begun to focus on emerging markets such as China.
Key players in the Global Diabetes Therapeutics market are increasingly extending their support to academic institutions to facilitate the R&D of innovative products for the treatment of diabetes. Collaborations in the market enable the amalgamation of research expertise of educational institutions with the marketing intelligence of pharma companies, as well as providing funds to conduct trials. To define the market conditions in the next 3-4 years, analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
Companies discussed in global type 2 diabetes therapeutics market 2015-2019 report include AstraZeneca, Novartis, Novo Nordisk, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck and Sanofi. Order a copy of this research at http://www.reportsnreports.com/Purchase.aspx?name=320342 .
Explore more diabetes market research and other newly published reports on pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts